NY-GENERAL-ATLANTIC
9.9.2019 12:02:09 CEST | Business Wire | Press release
Kiwi.com , a leading online travel booking platform powered by cutting-edge technology, today announced a new Board of Directors to guide the Company through its next phase of growth.
Daniel Finnegan, former Chief Financial Officer and Chief Accounting Officer of Booking Holdings (formerly The Priceline Group Inc.), will serve as an independent Board Director. During Mr. Finnegan’s 14-year tenure with Booking Holdings, the company grew to about 22,000 employees and reached a valuation of more than $100 billion.
“I am excited for the opportunity to work with Oliver and the Kiwi team as they build towards ambitious goals that will ultimately provide extraordinary value and experiences to travelers worldwide,” said Daniel Finnegan.
Kiwi.com executives Oliver Dlouhý, Co-founder and CEO, and Juraj Striezenec, CFO, as well as General Atlantic Technology sector team members Tanzeen Syed, Managing Director, and Jessie Cai, Vice President, will also join the Board.
“I am grateful to be surrounded by a group of experts with whom I look forward to closely working as we scale Kiwi.com,” said Oliver Dlouhý. “Our new Board brings a diversity of strategic and operational experience spanning the technology and travel sectors, and Dan’s background as the former CFO of one of the world’s largest travel companies will be invaluable to our business. The creation of this team is an exciting milestone in this next chapter of our growth.”
In June 2019 Kiwi.com announced a strategic investment from General Atlantic , a leading global growth investor, to help scale the business and support management’s vision to create a seamless end-to-end travel experience for customers. General Atlantic has extensive experience in the global online travel industry, with current and past investments including Priceline, Airbnb, Meituan, Flixbus, Uber, Despegar.com, Smiles and Mafengwo.
Tanzeen Syed continued, “We believe the structure and expertise of this Board well-positions Kiwi.com to execute on its vision of creating a comprehensive travel experience for consumers around the globe. The addition of an independent Director of the caliber and experience level of Dan brings further momentum to the business as Kiwi.com enters this next phase of growth. General Atlantic is excited to be working alongside Oliver, the Board and the Kiwi.com team to continue building a next-generation travel technology platform.”
Kiwi.com, a rapidly growing technology company, was founded in 2012 and was recognized as the #1 fastest-growing Czech start-up by Forbes Magazine in 2017 and 2018. Through its proprietary technology and algorithms, Kiwi.com has a unique ability to offer expansive flight options to value-conscious consumers.
The Company pioneered technology that matches passengers to multiple carriers and flights on single itineraries and partners with airlines, online travel agencies, and metasearch engines to sell more than €1 billion in tickets across the globe.
About Kiwi.com
Kiwi.com was founded in 2012 by Oliver Dlouhý and Jozef Képesi. The travel tech company was created for travellers by travellers. Its proprietary algorithm, Virtual Interlining, allows users to combine flights from more than 750 carriers, including many that do not normally cooperate. Kiwi.com also provides its industry-leading Kiwi.com Guarantee, which protects customers from missed connections because of delay, schedule change or cancellation.
Kiwi.com powers more than 100 million flight searches every day and employs over 2,900 people worldwide. It is one of the fastest-growing technology companies in Central Europe. It entered the 2017 Deloitte Technology Fast 500 EMEA list in 7th place, becoming the highest ever ranked Czech company. For the second consecutive year, Kiwi.com was named best Start-up of the Czech Republic by Czech Forbes Magazine in July 2018.
2018 saw the launch of NOMAD, a revolutionary multi-city travel search tool, and Tequila, a B2B platform for partners of all sizes. Also in 2018, Kiwi.com incorporated ground transportation into its search technology.
About General Atlantic
General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build exceptional businesses worldwide. General Atlantic has more than 150 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, and Singapore. For more information on General Atlantic, please visit the website: www.generalatlantic.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom